Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles
Open Access
- 26 October 2017
- journal article
- review article
- Published by Springer Nature in Cancer Nanotechnology
- Vol. 8 (1) , 1-19
Abstract
Chemotherapeutic agents have limited efficacy and resistance to them limits today and will limit tomorrow our capabilities of cure. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours. In front of this, multimodality has appeared as a promising strategy to overcome resistance. In this context, the use of nanoparticle-based platforms enables many possibilities to address cancer resistance mechanisms. Nanoparticles can act as carriers and substrates for different ligands and biologically active molecules, antennas for imaging, thermal and radiotherapy and, at the same time, they can be effectors by themselves. This enables their use in multimodal therapies to overcome the wall of resistance where conventional medicine crash as ageing of the population advance. In this work, we review the cancer resistance mechanisms and the advantages of inorganic nanomaterials to enable multimodality against them. In addition, we comment on the need of a profound understanding of what happens to the nanoparticle-based platforms in the biological environment for those possibilities to become a reality.Keywords
This publication has 145 references indexed in Scilit:
- Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectivesEMBO Molecular Medicine, 2012
- Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targetsClinical & Experimental Metastasis, 2012
- Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnologyJournal of Controlled Release, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Delivery of a peptide via poly(d,l-lactic-co-glycolic) acid nanoparticles enhances its dendritic cell–stimulatory capacityNanomedicine: Nanotechnology, Biology and Medicine, 2010
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progressionTrends in Immunology, 2010
- Matrix Crosslinking Forces Tumor Progression by Enhancing Integrin SignalingCell, 2009
- Circumventing Tumor Resistance to Chemotherapy by Nanotechnology2009
- Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®Biochemical Pharmacology, 2008
- Molecular mechanisms of drug resistanceThe Journal of Pathology, 2005